Seven purified metabolites of cyclosporin G (CsG) were studied for binding to cyclophilin and a 50-kDa binding protein (50-kDa BP). The ratios of the metabolite dissociation constants with respect to CsG were compared with in vitro immunosuppression by using the primary mixed lymphocyte suppression assay. The immunosuppressive potency ratio of the parent compounds, both cyclosporin A (C5A) and CsG, compared favorably with the drug dissociation constants for cyclophilin and the 50-kDa BP. Three of the seven metabolites had comparable binding and potency ratios for the 50-kDa BP. In contrast, none of the seven metabolites appreciably bound to cyclophilinin the concentration range tested. 
preventing allograft rejection, its use is limited by both reversible acute and irreversible chronic nephrotoxicity. Thus, numerous natural and synthetic analogs of CsA have been screened for similar immunosuppressive action in hopes that one or more analogs will be immunosuppressive but less toxic than CsA. Only a few of the analogs screened have shown promise as candidates to replace CsA (1). CsG has immunosuppressive potency similar to that of CsA (2) (3) (4) , although in initial animal studies some conflicting toxicity data, which may be species dependent, were reported (5) (6) (7) (8) .
CsG is now in clinical trials in humans. Phase-one studies for metabolism and pharmacokinetic studies have been carried out (9), and the metabolite pattern for ' 
Materials and Methods

Mixed lymphocyte culture (MLC) suppression assay.
The MLC assay was previously described (9 Figure 1 ). This indicates that the loss of a methyl group at amino acid 2 is not important for drug binding to the 50-kDa BP or cyclophilin ( Table  2 ). The hydroxylation of amino acid 1 (GM1) also does Table 2 . Structure of C5A, CsG, and Major Phase-I Metabolites 'Ml, aminoacId 1.
N, demethylation.
CC, cycllzatlon.
Abu, a-amino buty,ic acid; N-VaI, norvalino. One possible reason for this is that metabolite diffusion across the cell membrane may be, in part, a limiting factor in the immunosuppressive potency of these metabolites. If this hypothesis is correct, then any immunosuppressive metabolite that does not displace radiolabeled CsA from either cyclophilin or 50-kDa BP suggests that the binding protein is not involved in imrnunosuppression. None of the seven CsG metabolites bound to cyclophilin in the concentration range tested; however, two of the metabolites did exhibit -10% of the immunosuppressive activity of the parent compound. In our previous CsA metabolite study, we observed immunosuppressive activity with AM9, AM1, and AM4N (10). The 50-kDa BP did not bind AM9 and AM4N but bound AM1. Cyclophilin bound AM9, AM1, and AM4N, which in this study alone would make it a better target protein for CsA. However, with the observations from the CsA and CsG metabolite study, the results are more equivocal, because both proteins apparently do not bind to some of the immunosuppressive metabolites.
GM4N9. Supporting this observation is
Cyclophilin is a rotamase enzyme (15), and this activity can be inhibited by CsA. The 50-kDa BP is likely not a rotamase enzyme, because it failed to catalyze the cis-trans folding of several different peptides (J. G. Donnelly, S. J. Soldin, manuscript in preparation). Several groups have observed that the inhibition of rotamase activity is not required for iminunosuppression (16, 17) . However, it also was observed that the CsA 
